Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT03505021
Registration number
NCT03505021
Ethics application status
Date submitted
16/04/2018
Date registered
20/04/2018
Date last updated
11/05/2022
Titles & IDs
Public title
Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS
Query!
Scientific title
Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS
Query!
Secondary ID [1]
0
0
3119002
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
REFALS
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Amyotrophic Lateral Sclerosis
0
0
Query!
Condition category
Condition code
Neurological
0
0
0
0
Query!
Neurodegenerative diseases
Query!
Human Genetics and Inherited Disorders
0
0
0
0
Query!
Other human genetics and inherited disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Levosimendan
Treatment: Drugs - Placebo for levosimendan
Experimental: Levosimendan - Levosimendan 1 mg capsules for oral administration, once to twice a day. The total duration of treatment 48 weeks
Placebo comparator: Placebo for levosimendan - Placebo capsule for oral administration, once to twice a day. The total duration of treatment 48 weeks.
Treatment: Drugs: Levosimendan
Levosimendan 1 mg capsule for oral administration
Treatment: Drugs: Placebo for levosimendan
Placebo capsule for oral administration
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Supine Slow Vital Capacity (SVC)
Query!
Assessment method [1]
0
0
Change from baseline to 12 weeks, expressed as % of predicted normal.
Query!
Timepoint [1]
0
0
The change from baseline at 12 weeks
Query!
Secondary outcome [1]
0
0
Combined Assessment of Function and Survival Through 48 Weeks
Query!
Assessment method [1]
0
0
Scale: The ALS Functional Rating Scale - Revised. This scale includes 12 items. Each item was scored from 0 to 4. Total score is the sum of the scores of all 12 items. Each subject is ranked according to time-to-death (earlier deaths ranked lower than later deaths). Subjects who survive are ranked more favorably than subjects who died. Among the survivors, subjects are ranked according to change in ALSFRS-R (greater worsening of ALSFRS-R is ranked lower than after deaths). Subjects who survive are ranked more favorably than subjects who died. Among the survivors, subjects are ranked according to change in ALSFRS-R (greater worsening of ALSFRS-R is ranked lower than less worsening or an improvement in ALSFRS-R). The ranked scores range from 001 to 496 (the number of participants assessed for the Outcome Measure) with larger rank score numbers associated with a better outcome.
Query!
Timepoint [1]
0
0
Mean rank at 48 weeks
Query!
Secondary outcome [2]
0
0
Time to Respiratory Event Through 48 Weeks
Query!
Assessment method [2]
0
0
ALSFRS-R scale contains 3 items that relate to respiratory function: severity of dyspnoea, occurrence of orthopnoea (shortness of breath when lying flat) and the use of mechanical ventilation for respiratory insufficiency. A reduction in any one of these items was considered a respiratory event. Not all patients receive ventilatory support, despite respiratory insufficiency: meeting "protocolised" criteria for NIV relates to patients without NIV whose slow vital capacity declined to a level that would ordinarily trigger such treatment.
Query!
Timepoint [2]
0
0
Time to event through 48 weeks
Query!
Secondary outcome [3]
0
0
Change From the Baseline in Clinical Global Impression CGI at 48 Weeks
Query!
Assessment method [3]
0
0
Visual Analogue Scale 0-100 millimeters, rated by study subjects. Score 0 indicates that the subject is completely well without any disability and score 100 indicates the worst possible severity of the condition.
Query!
Timepoint [3]
0
0
The change from baseline at 48 weeks
Query!
Secondary outcome [4]
0
0
Change From Baseline in Respiratory Function of ALSFRS-R at 48 Weeks
Query!
Assessment method [4]
0
0
ALSFRS-R scale contains 3 items that relate to respiratory function: severity of dyspnoea, occurrence of orthopnoea (shortness of breath when lying flat) and the use of mechanical ventilation for respiratory insufficiency. These are added together to created the respiratory domain with a score range 0-12 (where 12 represents normal function). Although individual items and patients vary, ALSFRS-R typically declines at a relatively constant rate over time. Plotted over time the slope of the line obtained indicates the speed of progression and thus an effective treatment might be expected to reduce the slope of decline.
Query!
Timepoint [4]
0
0
Slope of decline at 48 weeks
Query!
Secondary outcome [5]
0
0
Supine Borg Category Ratio 10 Scale at 12 Weeks
Query!
Assessment method [5]
0
0
Patients rated their perception of the severity of their dysnoea using the Borg scale. The scale ranges from 0 (no dyspnoea) to 10 (maximal). Each category is numbered and most (not all) have verbal cues. At each assessment the patient scored the category they felt best described their symptoms. The analysis measured change from baseline at 12 weeks, where a negative score indicates improvement and a positive score reflects worsening.
Query!
Timepoint [5]
0
0
Change from baseline at 12 weeks
Query!
Eligibility
Key inclusion criteria
* Written or verbal informed consent (IC) for participation in the study
* Male or female subjects with diagnosis of laboratory supported probable, probable or definite ALS according to El Escorial revised criteria. Full electromyogram (EMG) report available consistent with ALS (but not necessarily fulfilling the electrodiagnostic criteria for ALS) from an experienced neurophysiologist
* Able to swallow study treatment capsules, and in the opinion of the investigator, is expected to continue to do so during the study
* Sitting SVC between 60-90% of the predicted value for age, height and sex at screening visit
* Disease duration from symptom onset (defined by first muscle weakness or dysarthria) 12-48 months at the time of visit 1 (baseline)
* Able to perform supine SVC in an adequate and reliable way at screening and baseline visits as judged by the investigator
* Subjects with or without riluzole and/or edaravone. If using riluzole (any daily dose up to 100 mg), the dose must have been stable for at least 4 weeks before the screening visit and should not be changed during the study. If using edaravone, the treatment should have been started at least 4 weeks before the screening visit (at least one 28-day treatment cycle as indicated) and should not be changed during the study. If not on riluzole and/or edaravone, the respective treatments should not be started during the study
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
120
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Subject in whom other causes of neuromuscular weakness have not been excluded
* Subject with a diagnosis of another neurodegenerative disease (e.g. Parkinson's or Alzheimer's disease)
* Assisted ventilation of any type within 3 months before the screening visit or at screening
* Any use of a diaphragm pacing system (DPS) within 3 months before the screening visit
* Any form of stem cell or gene therapy for the treatment of ALS
* Known hypersensitivity to levosimendan
* Administration of levosimendan within 3 months before the screening visit or previous participation in the present phase III study or earlier study with oral levosimendan in ALS patients (LEVALS)
* Any use of tirasemtiv or reldesemtiv within 1 month before the screening visit.
* Participation in a clinical trial with any experimental treatment within 30 days or within 5 half-lives of that treatment (whichever is longer) before the screening visit
* Any botulinum toxin use within 3 months before the screening visit
* Recorded diagnosis or evidence of major psychiatric diagnosis, significant cognitive impairment or clinically evident dementia that may interfere with the patient's ability to comply with study procedures
* Pulmonary illness (e.g. asthma or COPD) requiring regular treatment
* Haemodynamically significant uncorrected valve disease or hypertrophic cardiomyopathy or restrictive cardiomyopathy
* Any cardiovascular event (e.g. myocardial infarction, HF, arrhythmia or stroke) requiring hospitalisation within 3 months before the screening visit
* History of Torsades de Pointes (TdP) or diagnosed long QT-syndrome
* History of life-threatening ventricular arrhythmia, unless treated with reliable measures to prevent recurrence (e.g. with placement of implantable cardioverter defibrillator [ICD] or catheter ablation)
* History of second or third degree atrioventricular (AV) block or sinus node disease at screening, if not treated with pacemaker
* HR repeatedly > 100 bpm in the 12-lead ECG after a 5-minute rest at screening. If the HR is > 100 bpm in the first recording, then the second recording must be done after another 5 min rest to confirm HR > 100 bpm
* Systolic blood pressure (SBP) < 90 mmHg at screening
* Potassium < 3.7 mmol/l or > 5.5 mmol/l at screening
* Severe renal impairment (creatinine clearance < 30 ml/min at screening), creatinine > 170 µmol/l at screening or on dialysis
* Blood haemoglobin < 10 g/dl at screening or blood donation or loss of significant amount of blood within 60 days before the screening visit
* Clinically significant hepatic impairment at the discretion of the investigator
* Body mass index (BMI) = 18.5kg/m2 (BMI = weight/height2)
* Women who are lactating or of reproductive age without a negative pregnancy test and without a commitment to using a highly effective method of contraception (e.g. oral hormonal contraceptives associated with inhibition of ovulation, intrauterine devices and long acting progestin agents), if sexually active during the study, and for 1 month after the last dose of the study treatment. Women who are postmenopausal (1 year since last menstrual cycle), surgically sterilised or who have undergone a hysterectomy are considered not to be reproductive and can be included
* Patient judged to be actively suicidal by the investigator during 3 months before the screening visit
* Patients with known history of human immunodeficiency virus (HIV) infection
* Any other clinically significant cardiovascular, gastrointestinal, hepatic, renal, neurological or psychiatric disorder or any other major concurrent illness that in the opinion of the investigator could interfere with the interpretation of the study results or constitute a health risk for the subject if he/she took part in the study
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
21/06/2018
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
23/07/2020
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
496
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,VIC,WA
Query!
Recruitment hospital [1]
0
0
Brain and Mind Centre - Camperdown
Query!
Recruitment hospital [2]
0
0
Royal Brisbane and Women's Hospital - Brisbane
Query!
Recruitment hospital [3]
0
0
Flinders Medical Centre - Bedford Park
Query!
Recruitment hospital [4]
0
0
Calvary Health Care Bethlehem - Caulfield South
Query!
Recruitment hospital [5]
0
0
Perron Institute for Neurological and Translational Science - Murdoch
Query!
Recruitment postcode(s) [1]
0
0
2050 - Camperdown
Query!
Recruitment postcode(s) [2]
0
0
4029 - Brisbane
Query!
Recruitment postcode(s) [3]
0
0
5042 - Bedford Park
Query!
Recruitment postcode(s) [4]
0
0
3162 - Caulfield South
Query!
Recruitment postcode(s) [5]
0
0
6150 - Murdoch
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arizona
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Colorado
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Connecticut
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
District of Columbia
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Florida
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Georgia
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Illinois
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Kentucky
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Maryland
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Massachusetts
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Michigan
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Minnesota
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Missouri
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Nebraska
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
New York
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
North Carolina
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Ohio
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Oregon
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Pennsylvania
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Texas
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
Utah
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
Vermont
Query!
Country [24]
0
0
United States of America
Query!
State/province [24]
0
0
Washington
Query!
Country [25]
0
0
United States of America
Query!
State/province [25]
0
0
Wisconsin
Query!
Country [26]
0
0
Austria
Query!
State/province [26]
0
0
Tyrol
Query!
Country [27]
0
0
Austria
Query!
State/province [27]
0
0
Upper Austria
Query!
Country [28]
0
0
Austria
Query!
State/province [28]
0
0
Wien
Query!
Country [29]
0
0
Belgium
Query!
State/province [29]
0
0
Flemish Brabant
Query!
Country [30]
0
0
Belgium
Query!
State/province [30]
0
0
Liege
Query!
Country [31]
0
0
Belgium
Query!
State/province [31]
0
0
Oost-Vlaanderen
Query!
Country [32]
0
0
Canada
Query!
State/province [32]
0
0
Alberta
Query!
Country [33]
0
0
Canada
Query!
State/province [33]
0
0
New Brunswick
Query!
Country [34]
0
0
Canada
Query!
State/province [34]
0
0
Ontario
Query!
Country [35]
0
0
Canada
Query!
State/province [35]
0
0
Quebec
Query!
Country [36]
0
0
Finland
Query!
State/province [36]
0
0
Helsinki
Query!
Country [37]
0
0
Finland
Query!
State/province [37]
0
0
Lappeenranta
Query!
Country [38]
0
0
Finland
Query!
State/province [38]
0
0
Turku
Query!
Country [39]
0
0
France
Query!
State/province [39]
0
0
Limoges
Query!
Country [40]
0
0
France
Query!
State/province [40]
0
0
Montpellier
Query!
Country [41]
0
0
France
Query!
State/province [41]
0
0
Nice
Query!
Country [42]
0
0
France
Query!
State/province [42]
0
0
Tours
Query!
Country [43]
0
0
Germany
Query!
State/province [43]
0
0
Baden-Württemberg
Query!
Country [44]
0
0
Germany
Query!
State/province [44]
0
0
Hessen
Query!
Country [45]
0
0
Germany
Query!
State/province [45]
0
0
Mecklenburg-western-pommerania
Query!
Country [46]
0
0
Germany
Query!
State/province [46]
0
0
Niedersachsen
Query!
Country [47]
0
0
Germany
Query!
State/province [47]
0
0
Nordrhein-westfalen
Query!
Country [48]
0
0
Germany
Query!
State/province [48]
0
0
Nordrhein-Westfalen
Query!
Country [49]
0
0
Germany
Query!
State/province [49]
0
0
Sachsen
Query!
Country [50]
0
0
Germany
Query!
State/province [50]
0
0
Thuringen
Query!
Country [51]
0
0
Germany
Query!
State/province [51]
0
0
Berlin
Query!
Country [52]
0
0
Ireland
Query!
State/province [52]
0
0
Dublin
Query!
Country [53]
0
0
Italy
Query!
State/province [53]
0
0
Genova
Query!
Country [54]
0
0
Italy
Query!
State/province [54]
0
0
Novara
Query!
Country [55]
0
0
Italy
Query!
State/province [55]
0
0
Pavia
Query!
Country [56]
0
0
Italy
Query!
State/province [56]
0
0
Pisa
Query!
Country [57]
0
0
Italy
Query!
State/province [57]
0
0
Roma
Query!
Country [58]
0
0
Italy
Query!
State/province [58]
0
0
Torino
Query!
Country [59]
0
0
Netherlands
Query!
State/province [59]
0
0
Noord-Holland
Query!
Country [60]
0
0
Netherlands
Query!
State/province [60]
0
0
Utrecht
Query!
Country [61]
0
0
Spain
Query!
State/province [61]
0
0
Vizcaya
Query!
Country [62]
0
0
Spain
Query!
State/province [62]
0
0
Barcelona
Query!
Country [63]
0
0
Spain
Query!
State/province [63]
0
0
Córdoba
Query!
Country [64]
0
0
Spain
Query!
State/province [64]
0
0
Madrid
Query!
Country [65]
0
0
Spain
Query!
State/province [65]
0
0
Valencia
Query!
Country [66]
0
0
Sweden
Query!
State/province [66]
0
0
Vasterbotten
Query!
Country [67]
0
0
Sweden
Query!
State/province [67]
0
0
Karlstad
Query!
Country [68]
0
0
Sweden
Query!
State/province [68]
0
0
Stockholm
Query!
Country [69]
0
0
United Kingdom
Query!
State/province [69]
0
0
England
Query!
Country [70]
0
0
United Kingdom
Query!
State/province [70]
0
0
Liverpool
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Orion Corporation, Orion Pharma
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This study will evaluate whether prolonged oral levosimendan can preserve respiratory function more effectively than placebo, resulting in better patient functionality as measured by the ALSFRS-R scale. In this randomized, double-blind, placebo-controlled, parallel-group, multicenter study, subjects are allocated in a 2:1 ratio to receive either levosimendan (1 -2 mg daily) or placebo for 48 weeks. The primary endpoint is slow vital capacity (SVC) at 12 weeks, with the impact on patient function assessed through 48 weeks, adjusted for patient outcome, using ALSFRS-R (combined assessment of function and survival, CAFS). Other important efficacy measures include time to respiratory events, clinical global impression (CGI), assessment of dyspnea using the Borg scale and sleep scales (Pittsburgh sleep quality index and Epworth sleepiness scale). Patient safety is monitored using conventional methods including adverse events, safety laboratory tests, vital signs and 12-lead EKG. Following screening and baseline visits, patients attend the clinic at 2, 4, 8, 12, 24, 36 and 48 weeks, with telephone assessments conducted at weeks 18, 30 and 42. An end of study visit is performed 14-25 days after the last study treatment administration. The study will be monitored by an independent data and safety monitoring board. A long-term extension study will be available for patients completing the study.
Query!
Trial website
https://clinicaltrials.gov/study/NCT03505021
Query!
Trial related presentations / publications
Cudkowicz M, Genge A, Maragakis N, Petri S, van den Berg L, Aho VV, Sarapohja T, Kuoppamaki M, Garratt C, Al-Chalabi A; REFALS investigators. Safety and efficacy of oral levosimendan in people with amyotrophic lateral sclerosis (the REFALS study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Neurol. 2021 Oct;20(10):821-831. doi: 10.1016/S1474-4422(21)00242-8.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Merja Mäkitalo, CSD
Query!
Address
0
0
Orion Corporation, Orion Pharma
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Type
Other Details
Attachment
Study protocol
https://cdn.clinicaltrials.gov/large-docs/21/NCT03505021/Prot_000.pdf
Statistical analysis plan
https://cdn.clinicaltrials.gov/large-docs/21/NCT03505021/SAP_001.pdf
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results are available at
https://clinicaltrials.gov/study/NCT03505021
Download to PDF